Christopher Knight, MD
Ophthalmology · Warsaw, INNPI 1659374205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,750 of the $6,993 with a category attached, or 82.2%. 23 manufacturers reported payments, led by Alcon at 59.3% of the total.
Across 150 payments — averaging $46.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- Rxsight Inc$1K
- Glaukos Corporation$582
- AbbVie$264
- Novartis$157
- Sight Sciences, Inc.$104
- plus $559 from 17 others
What the payments were for
- Speaking & faculty fees$260%
- Travel & lodging$1,17717%
- Food & beverage$5,75082%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 70 | $4,148 |
| Rxsight Inc | 19 | $1,179 |
| Glaukos Corporation | 13 | $582 |
| AbbVie(2 entities) | 13 | $264 |
| Novartis | 3 | $157 |
| Sight Sciences, Inc. | 2 | $104 |
| Lensar, Inc. | 1 | $83 |
| NEW World Medical,inc. | 5 | $63 |
| Ocular Therapeutix, Inc. | 3 | $52 |
| Apellis Pharmaceuticals, Inc. | 3 | $52 |
| Astellas Pharma US Inc | 2 | $41 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $36 |
| Omeros Corporation | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Aerie Pharmaceuticals, Inc. | 2 | $33 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Alimera Sciences, Inc. | 1 | $16 |
| Dompe US, Inc. | 1 | $15 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Carl Zeiss Meditec USA, Inc. | 1 | $14 |
| Eyepoint US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,647
- ARGOS$1,292
- Centurion$1,177
- RXSIGHT CONTACT LENS$549
- RXSIGHT INJECTOR CARTRIDGE$549
- RXSIGHT INJECTOR HANDPIECE$549
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$549
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$392
- LenSx$288
- LIGHT ADJUSTABLE LENS (LAL)$275
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$273
- iDoseTR$175
- AcrySof IQ PanOptix UV IOL$157
- Hydrus Microstent$149
- AcrySof$142
- AcrySof IQ PanOptix$129
- iStent inject W$110
How this compares
$6,993 in reported general payments places this provider in the 85th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 190 | $89,806 |
| RhopressaNetarsudil Mesylate | 107 | $53,466 |
| RocklatanNetarsudil Mesylat/Latanoprost | 59 | $33,443 |
| Alphagan PBrimonidine Tartrate | 43 | $17,227 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $13,297 |
| Travoprost | 92 | $10,179 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 830 | $9,525 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 83 | $7,096 |
| ZirganGanciclovir | 14 | $6,557 |
| Prednisolone Acetate | 177 | $6,368 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 29 | $5,793 |
| Loteprednol Etabonate | 26 | $4,444 |
| Difluprednate | 58 | $4,365 |
| Latanoprost | 788 | $4,130 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 24 | $3,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan | $264 | $120,330263 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $33 | $86,909166 claims |
| Bausch & Lomb Americas Inc.Zirgan | $18 | $6,55714 claims |
| AlconSimbrinza | $4,148 | $5,79329 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $15 | $4,44426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Warsaw
- Bruce GrossnickleWarsaw$16K
- Ann Buikema-WiardaWarsaw$13K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.